Rare childhood interstitial lung diseases (chILD) are chronic respiratory conditions causing lung inflammation and scarring. Symptoms include breathing difficulties, persistent cough, and poor growth, with limited treatment options. Evaluating patient well-being through health-related quality of life (HRQoL) is crucial for effective care.
A European study of 424 children found recent hospital admissions were strongly linked to lower HRQoL, with scores dropping 11-14%. This highlights the significant physical and emotional toll of intensive medical treatment.
Furthermore, failure to thrive, or insufficient growth, was associated with a 9-12% decrease in HRQoL. This indicates that growth impairment, often tied to disease severity, profoundly affects a child's daily life, social interactions, and overall wellbeing.
Conventional lung function tests showed a weak correlation with HRQoL, suggesting these metrics alone do not fully capture the patient experience. The findings emphasize the need to target factors like hospitalization burden and nutritional status to improve quality of life.
Integrating HRQoL assessments into routine care can help identify at-risk children and prioritize interventions addressing both medical and developmental needs.